Corrigendum to “Pharmacotherapy for NASH: Current and emerging” [J Hepatol 68 (2017) 362–375](S0168827817323942)(10.1016/j.jhep.2017.10.015);Pharmacotherapy for NASH: Current and emerging

Journal of Hepatology

Volumn 68, Issue 2, 2018, Pages 362-375

  Konerman, Monica A ^a   Jones, Jacob C ^b   Harrison, Stephen A ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical trials; Fibrosis; Hepatitis; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

ACETYL COENZYME A CARBOXYLASE INHIBITOR; ARAMCHOL; BI 1467335; BMS 986026; BMS 986036; CARBOHYDRATE DERIVATIVE; CENICRIVIROC; ELAFIBRANOR; EMRICASAN; FIBROBLAST GROWTH FACTOR 19; GR MD 02; GS 0976; GS 9674; GS 976; HORMONE RECEPTOR STIMULATING AGENT; JKB 121; LANIFIBRANOR; LIK 066; LJN 452; LMB 763; MGL 3196; MSDC 0602K; NGM 282; OBETICHOLIC ACID; PF 05221304; RECOMBINANT CYTOKINE; SAROGLITAZAR; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLIXIBAT;

COMBINATION DRUG THERAPY; DISEASE BURDEN; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DISEASE EXACERBATION; MEDICATION THERAPY MANAGEMENT; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; MEDICATION THERAPY MANAGEMENT; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

EID: 85034431499     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.03.002     Document Type: Erratum

References (104)

1. World Health Organization. Obesity and Overweight: Fact Sheet. 2016. http://www.who.int/mediacentre/factsheets/fs311/en.
2. World Health Organization. Media Centre- Diabetes. http://www.who.int/mediacentre/factsheets/fs312/en/.
3. Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
4. Leite, N.C., Salles, G.F., Araujo, A.L., et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29 (2009), 113–119.
5. Fruci, B., Giuliano, S., Mazza, A., et al. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 14 (2013), 22933–22966.
6. Assy, N., Kaita, K., Mymin, D., et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45 (2000), 1929–1934.
7. Wu, K.T., Kuo, P.L., Su, S.B., et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol 10 (2016), 420–425 e1.
8. Sasaki, A., Nitta, H., Otsuka, K., et al. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol, 5, 2014, 164.
9. Subichin, M., Clanton, J., Makuszewski, M., et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis 11 (2015), 137–141.
10. Donati, G., Stagni, B., Piscaglia, F., et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 53 (2004), 1020–1023.
11. Pan, J.J., Fallon, M.B., Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 6 (2014), 274–283.
12. Weston, S.R., Leyden, W., Murphy, R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41 (2005), 372–379.
13. Dongiovanni, P., Anstee, Q.M., Valenti, L., Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 19 (2013), 5219–5238.
14. Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
15. Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
16. Dunn, W., Xu, R., Wingard, D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103 (2008), 2263–2271.
17. National Institute of Health. NIDDK> Health Information> Health Topics> Liver Diseases> Cirrhosis 2016. https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis.
18. Koehler, E., Watt, K., Charlton, M., Fatty liver and liver transplantation. Clin Liver Dis 13 (2009), 621–630.
19. Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
20. Parikh, N.D., Marrero, W.J., Wang, J., et al. Projected increase in obesity and non-alcoholic steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology, 2017.
21. Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 e10.
22. Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
23. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology, 2017.
24. Dong, Y.P., Chen, Q., Cui, S.H., et al. Enumeration, genetic characterization and antimicrobial susceptibility of Lactobacillus and Streptococcus isolates from retail yoghurt in Beijing, China. Biomed Environ Sci 27 (2014), 740–748.
25. Sanyal, A.J., Chalasani, N., Kowdley, K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
26. Bjelakovic, G., Nikolova, D., Gluud, L.L., et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007), 842–857.
27. Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306 (2011), 1549–1556.
28. Miller, E.R. 3rd, Pastor-Barriuso, R., Dalal, D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005), 37–46.
29. Boettcher, E., Csako, G., Pucino, F., et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 35 (2012), 66–75.
30. Mahady, S.E., Webster, A.C., Walker, S., et al. The role of thiazolidinediones in non-alcoholic steatohepatitis – a systematic review and meta analysis. J Hepatol 55 (2011), 1383–1390.
31. Cusi, K., Orsak, B., Bril, F., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165 (2016), 305–315.
32. Nesto, R.W., Bell, D., Bonow, R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004), 256–263.
33. Lecka-Czernik, B., Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 8 (2010), 178–184.
34. Hannah, W.N. Jr., Torres, D.M., Harrison, S.A., Nonalcoholic steatohepatitis and endpoints in clinical trials. Gastroenterol Hepatol 12 (2016), 756–763.
35. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
36. Bedossa, P., Poitou, C., Veyrie, N., et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56 (2012), 1751–1759.
37. Sanyal, A.J., Brunt, E.M., Kleiner, D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54 (2011), 344–353.
38. Harrison, S., Praca, E., Brozek, J., et al. A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH. J Hepatol, 66, 2017, S110.
39. Park, C.C., Nguyen, P., Hernandez, C., et al. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152 (2017), 598–607 e2.
40. Pavlides, M., Banerjee, R., Tunnicliffe, E.M., et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int 37 (2017), 1065–1073.
41. Sasso, M., Audiere, S., Kemgang, A., et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the fibroscan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol 42 (2016), 92–103.
42. Dulai, P.S., Sirlin, C.B., Loomba, R., MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol 65 (2016), 1006–1016.
43. Rensen, S.S., Slaats, Y., Driessen, A., et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 50 (2009), 1809–1817.
44. Friedrich-Rust, M., Rosenberg, W., Parkes, J., et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol, 10, 2010, 103.
45. Angulo, P., Hui, J.M., Marchesini, G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
46. Shah, A.G., Lydecker, A., Murray, K., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7 (2009), 1104–1112.
47. Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654 [Quiz e39–e40].
48. Fierbinteanu-Braticevici, C., Plesca, D.A., Tribus, L., et al. The role of (1)(3)C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease. J Gastrointestin Liver Dis 22 (2013), 149–156.
49. Helmke, S.M., Marr, J.D., Cookson, M.W., et al. Diagnosing of NASH and assessing NASH disease severity by a global measure of liver function, the HepQuant® (HQ)-SHUNT test. Hepatology, 63, 2016, 584A.
50. Covance. NASH: Key considerations for drug development. https://www.covance.com/content/dam/covance/assetLibrary/whitepapers/NASH%20White%20Paper-WPCDS008.pdf.
51. Filozof, C., Chow, S.-C., Dimick-Santos, L., et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatol Commun 1 (2017), 577–585.
52. Ghevariya, V., Sandar, N., Patel, K., et al. Knowing what's out there: awareness of non-alcoholic fatty liver disease. Front Med, 1, 2014, 4.
53. Wieland A, Mettler P, McDermott M, et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk, 2014.
54. Wieland, A.C., Quallick, M., Truesdale, A., et al. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci 58 (2013), 2809–2816.
55. Konerman MA WP, Jackson E, Lok AS, Rubenfire M. Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-Alcoholic Fatty Liver Disease. AASLD Emerging Trends in NAFLD Conference 2017.
56. Losekann, A., Weston, A.C., de Mattos, A.A., et al. Non-alcoholic steatohepatitis (NASH): risk factors in morbidly obese patients. Int J Mol Sci 16 (2015), 25552–25559.
57. Noureddin, M., Yates, K.P., Vaughn, I.A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58 (2013), 1644–1654.
58. Loomba, R., Abraham, M., Unalp, A., et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56 (2012), 943–951.
59. Harrison SA AM, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MB, Ling L, Rossi SJ, DePaoli AM, Rinella ME, Loomba R. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. EASL 2017, 2017.
60. Sanyal A CE, Neuschwander-Tetri B, Loomba R, Harrison S, Abdelmalek MF, Lawitz E, Halegoua-Demarzio D, Dong Y, Noviello S, Krishnamoorthy S, Luo Y, Christian R. BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: A phase 2 study EASL 2017, 2017.
61. Iwasaki, S., Hamada, T., Chisaki, I., et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the glucagon-like peptide-1 receptor agonist exenatide to characterize its antiobesity effects in diet-induced obese mice. J Pharmacol Exp Ther 362 (2017), 441–449.
62. Armstrong, M.J., Gaunt, P., Aithal, G.P., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
63. Samuel, V.T., Shulman, G.I., Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab, 2017.
64. Kim, C.W., Addy, C., Kusunoki, J., et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab, 26, 2017, 576.
65. Clinical Trials.gov. Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD). https://clinicaltrials.gov/ct2/show/NCT03248882.
66. Gilead.com. Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017 | Gilead. http://www.gilead.com/news/press-releases/2017/4/gilead-presents-proofofconcept-data-for-gs0976-in-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2017.
67. Clinical Trials.gov. GS-0976 in Adults With Nonalcoholic Steatohepatitis. https://clinicaltrials.gov/ct2/show/NCT02856555.
68. Adar, T., Ben Ya'acov, A., Lalazar, G., et al. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol 167 (2012), 252–260.
69. Mizrahi, M., Shabat, Y., Ben Ya'acov, A., et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res 5 (2012), 141–150.
70. Clinical Trials.gov. A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis. https://clinicaltrials.gov/ct2/show/NCT02316717.
71. Safadi, R., Konikoff, F.M., Mahamid, M., et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12 (2014), 2085–2091 e1.
72. Clinical Trials.gov. A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (Aramchol_005). https://clinicaltrials.gov/ct2/show/NCT02279524.
73. Barreyro, F.J., Holod, S., Finocchietto, P.V., et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int 35 (2015), 953–966.
74. Garcia-Tsao F, McGuire, Shiffman ML, Chan JL, Morris M, Yamashita M, Spada AP, Hagerty D. TITLE: Emricaaan (IDN-8556) administered orally for 28 days lowers portal pi'II88Ure in patients with compensatedcirrhosis and severe portal hypertension AASLD Liver Meeting 2015, 2015.
75. Clinical Trials.gov. Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF). https://clinicaltrials.gov/ct2/show/NCT02686762.
76. Clinical Trials.gov. Emricasan, a Caspase Inhibitor, or Treatment of Subjects With Decompensated NASH Cirrhosis (ENCORE-LF). https://clinicaltrials.gov/ct2/show/NCT03205345?term=emricasan&draw=1&rank=1.
77. Ir.conatuspharma.com. Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis (NASDAQ:CNAT). http://ir.conatuspharma.com/releasedetail.cfm?releaseid=1024672.
78. Traber, P.G., Chou, H., Zomer, E., et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One, 8, 2013, e75361.
79. Clinical Trials.gov. Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis (NASH-FX). https://clinicaltrials.gov/ct2/show/NCT02421094.
80. Clinical Trials.gov. Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). https://clinicaltrials.gov/ct2/show/NCT02462967.
81. Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 574–582 e1.
82. Fuchs, M., Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids, 2012, 2012, 934396.
83. Ali, A.H., Carey, E.J., Lindor, K.D., Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med, 3, 2015, 5.
84. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
85. Ratziu, V., Sanyal, A.J., MacConell, L., et al. Regenerate: A phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis. J Hepatol 64 (2016), S294–S295.
86. Staels, B., Rubenstrunk, A., Noel, B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58 (2013), 1941–1952.
87. Tailleux, A., Wouters, K., Staels, B., Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821 (2012), 809–818.
88. Poulsen, L., Siersbaek, M., Mandrup, S., PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 23 (2012), 631–639.
89. Riserus, U., Sprecher, D., Johnson, T., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57 (2008), 332–339.
90. Ratziu, V., Harrison, S.A., Francque, S., et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150 (2016), 1147–1159 e5.
91. Ratziu, V.F.S., Harrison, S., et al. Improvement in NASH histological activity highly correlates with fibrosis regression. Hepatology 64 (2016), 1118A–1140A.
92. Clinical Trials.gov. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE). https://clinicaltrials.gov/ct2/show/NCT02548351.
93. Seki, E., de Minicis, S., Inokuchi, S., et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50 (2009), 185–197.
94. Lefebvre, E., Moyle, G., Reshef, R., et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist Cenicriviroc in animal models of liver and kidney fibrosis. PLoS One, 11, 2016, e0158156.
95. Lefebvre, E., Gottwald, M., Lasseter, K., et al. Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of Cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci 9 (2016), 139–148.
96. Miura, K., Yang, L., van Rooijen, N., et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302 (2012), G1310–G1321.
97. Friedman, S.L., Ratziu, V., Harrison, S.A., et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology, 2017.
98. Clinical Trials gov. AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH. https://clinicaltrials.gov/ct2/show/NCT03028740.
99. Hashem, R.M., Hassanin, K.M., Rashed, L.A., et al. Effect of silibinin and vitamin E on the ASK1-p38 MAPK pathway in D-galactosamine/lipopolysaccharide induced hepatotoxicity. Exp Biol Med 241 (2016), 1250–1257.
100. Loomba RLE, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Mae Diehl AM, et al. GS-4997, an Inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): a randomized, phase 2 trial AASLD liver meeting 2016, 2016.
101. Clinical Trials.gov. Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4). https://clinicaltrials.gov/ct2/show/NCT03053063.
102. Clinical Trials.gov. Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3). https://clinicaltrials.gov/ct2/show/NCT03053050.
103. Clinical Trials.gov. Safety, Tolerability, and Efficacy of Selonsertib, GS-0976, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH). https://clinicaltrials.gov/ct2/show/NCT02781584.
104. Gilead Sciences. Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017. http://www.gilead.com/news/press-releases/2017/4/gilead-to-present-clinical-and-preclinical-data-on-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2017.